Sustained release ophthalmic drug dosage

Drug – bio-affecting and body treating compositions – Solid synthetic organic polymer as designated organic active... – Polymer from ethylenic monomers only

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

424 81, 424181, 424273R, 424283, 424300, 424324, 424331, A61K 3174, A61K 3178, A61K 3171, A61K 3135

Patent

active

042711436

ABSTRACT:
The present invention is directed to an aqueous dispersion of an ophthalmic drug and a high molecular weight polymer which forms a highly viscous gel and can be used to prolong the duration of activity of the ophthalmic drug when the gel is applied into the conjunctival sac of the eye. The ophthalmic drug-containing gel composition has prolonged retention time in the eye and remains in contact with the surface of the eye for an extended period of time.

REFERENCES:
patent: 2707777 (1955-03-01), Feinstein et al.
patent: 2798053 (1957-07-01), Brown
patent: 3214338 (1965-10-01), Ehrlich
patent: 3947573 (1976-03-01), Rankin
patent: 3966902 (1976-06-01), Chromecek
patent: 4003991 (1977-01-01), Krohn et al.
J. Pharm. Sciences 67(9), pp. 1280-1283, (1978), Schoenwald et al.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Sustained release ophthalmic drug dosage does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sustained release ophthalmic drug dosage, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release ophthalmic drug dosage will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1865044

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.